James Frederick, PA-C, MMSc,  —

African- and Hispanic-Americans are less likely than whites to receive care for neurological diseases such as multiple sclerosis in a doctor’s office or clinic, according to a study. Many of them end up in a hospital emergency room after failing to obtain treatment that could have helped them avoid an…

Nektar Therapeutics has started a Phase 1 clinical trial of its biologic therapy NKTR-358 for inflammatory disorders and autoimmune diseases like multiple sclerosis. NKTR-358 is a first-in-class regulatory T-cell stimulator designed to correct the immune system dysfunction associated with these disorders. It targets regulatory T-cells, or Tregs. Other immunosuppressant therapies suppress the…